RECORD // Company

Bolt Biotherapeutics, Inc.

Formerly: Bolt Therapeutics, Inc.

Built 2026-11-22T00:23:56Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Bolt Biotherapeutics, Inc. · Ctgov · same registered legal name as 'Bolt Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BOLT BIOTHERAPEUTICS INC · Epa echo · same registered legal name as 'Bolt Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001193125-26-458877

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-130001193125-26-4588772026-11-22 00:23 UTCReport an error
Net income (loss)$-4,422,0003 months ended 2026-09-3010-Q2026-11-130001193125-26-4588772026-11-22 00:23 UTCReport an error
Cash and cash equivalents$13,782,000at 2026-09-3010-Q2026-11-130001193125-26-4588772026-11-22 00:23 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001641281
Ticker
BOLT
EIN
472804636
CUSIP
097702203
Record ID
sx:sec:0001641281

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

36 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-17SEC EDGAR company profile2026-11-22 00:23 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-17SEC EDGAR company profile2026-11-22 00:23 UTCReport an error
State of incorporationDE2026-11-17SEC EDGAR company profile2026-11-22 00:23 UTCReport an error
Fiscal year end (MMDD)12312026-11-17SEC EDGAR company profile2026-11-22 00:23 UTCReport an error
Business address900 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 940632026-11-17SEC EDGAR company profile2026-11-22 00:23 UTCReport an error
ExchangesNasdaq2026-11-17SEC EDGAR company profile2026-11-22 00:23 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$7,695,0002025-12-3110-K, XBRL Revenues2026-11-22 00:23 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-33,376,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:23 UTCReport an error
Total assets (at 2025-12-31)$56,748,0002025-12-3110-K, XBRL Assets2026-11-22 00:23 UTCReport an error
Stockholders' equity (at 2025-12-31)$26,505,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:23 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$11,703,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:23 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-39,850,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:23 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$72,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:23 UTCReport an error
Operating lease liabilities (at 2025-12-31)$22,958,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:23 UTCReport an error
Form D total offering amount (D filed 2021-06-07)$15,000,0002021-06-07D2026-11-22 00:23 UTCReport an error
Form D total amount sold (D filed 2021-06-07)$15,000,0002021-06-07D2026-11-22 00:23 UTCReport an error
Form D industry groupBiotechnology2021-06-07D2026-11-22 00:23 UTCReport an error
Form D revenue rangeDecline to Disclose2021-06-07D2026-11-22 00:23 UTCReport an error
Form D date of first sale2021-06-012021-06-07D2026-11-22 00:23 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026 and a business update. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained herein and the accompanying exhibit is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and…2026-11-12SEC EDGAR 8-K 0001193125-26-458403 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-23)Agreement and Plan of Merger On October 23, 2026, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company” or “Bolt”), acquired Prana Therapies, Inc., a Delaware corporation (“Prana”), in accordance with the terms of the Agreement and Plan of Merger, dated October 23, 2026 (the “Merger Agreement”), by and among the Company, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Prana. Pursuant to the Merger Agreement, First Merger Sub merged with and into Prana, pursuant to which Prana was…2026-10-23SEC EDGAR 8-K 0001193125-26-429647 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
8-K Item 1.02, Termination of a Material Definitive Agreement (filed 2026-10-23)Lease Agreement Termination As previously disclosed, on October 1, 2026, the Company entered into a Second Amendment to Lease (the “Second Lease Amendment”) with HCP LS Redwood City LLC, as landlord. Pursuant to the Second Lease Amendment, the financing and strategic transaction described herein triggers termination of the agreement and payment of the $4.5 million termination payment.2026-10-23SEC EDGAR 8-K 0001193125-26-429647 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
8-K Item 2.01, Completion of Acquisition or Disposition of Assets (filed 2026-10-23)On October 23, 2026, the Company completed its business combination with Prana. The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.2026-10-23SEC EDGAR 8-K 0001193125-26-429647 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-23)The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The PIPE Securities (including the Warrants and shares of Common Stock (or for shares of Series D Preferred Stock under certain circumstances), in each case issuable upon exercise thereof) and shares of Series D Preferred Stock issued pursuant to the Merger Agreement were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the Investors represented that it was an “accredited investor,” as defined in Regulation D, and is acquiring the PIPE Securities…2026-10-23SEC EDGAR 8-K 0001193125-26-429647 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-06)Lease Agreement Amendment On October 1, 2026, Bolt Biotherapeutics, Inc. (the “Company”) entered into the Second Amendment to Lease (the “Second Lease Amendment”) with HCP LS Redwood City LLC, as landlord (the “Landlord”). The Second Lease Amendment amends that certain lease agreement, dated August 7, 2020, as previously amended (the “Chesapeake Master Lease”), by and between the Landlord and the Company, relating to the Company’s corporate office, laboratory and vivarium facilities located at 800 and 900 Chesapeake Drive, Redwood City, California (collectively, the “Premises”). Pursuant to the execution of the Second Lease Amendment, the Company paid the Landlord $1.0 million and…2026-10-06SEC EDGAR 8-K 0001193125-26-415560 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-11)On August 11, 2026, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026 and a business update. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained herein and the accompanying exhibit is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange…2026-08-11SEC EDGAR 8-K 0001193125-26-344580 (text as filed, excerpt)2026-11-22 00:23 UTCReport an error
Largest institutional holder #1 (13F as filed): Sofinnova Investments, Inc.$530,2262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #2 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$379,7062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #3 (13F as filed): Vivo Capital, LLC$278,7942026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #4 (13F as filed): CITADEL ADVISORS LLC$219,0772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #5 (13F as filed): T3 Companies, LLC$146,3002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #6 (13F as filed): Board of Trustees of The Leland Stanford Junior University$138,5112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #7 (13F as filed): Pfizer Inc$133,8322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #8 (13F as filed): Lynx1 Capital Management LP$118,5802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #9 (13F as filed): NANO CAP NEW MILLENNIUM GROWTH FUND L P$105,8752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$73,6222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:23 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.